DexCom, Inc. · NASDAQ (us_market)
Healthcare · Medical Devices · United States
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-26$74.38 RISE2026-04-29$57.56 PEAK2026-05-29$73.74 92d | -22.6% 62d | 2026-04-30 $59.55 | Missed | 67Quality on Sale | — | +28.1% 30d | Missed |
DROP2025-07-28$89.53 RISE2025-11-10$54.84 PEAK2026-01-29$74.00 185d | -38.7% 105d | Missed | Missed | — | — | +34.9% 80d | Missed |
DROP2025-02-24$90.75 RISE2025-04-04$59.83 PEAK2025-06-24$87.57 120d | -34.1% 39d | Missed | Missed | — | — | +46.4% 81d | Missed |
DROP2024-05-29$127.64 RISE2024-10-03$65.68 PEAK2024-12-04$81.01 189d | -48.5% 127d | Missed | Missed | — | — | +23.3% 62d | Missed |
DROP2024-04-09$140.45 RISE2024-07-26$64.00 PEAK2024-08-19$77.69 132d | -54.4% 108d | Missed | Missed | — | — | +21.4% 24d | Missed |
DROP2023-07-18$137.93 RISE2023-10-12$75.49 PEAK2024-01-09$129.70 175d | -45.3% 86d | Missed | Missed | — | — | +71.8% 89d | Missed |
DROP2022-12-08$122.67 RISE2023-01-25$104.00 PEAK2023-04-19$124.12 132d | -15.2% 48d | Missed | Missed | — | — | +19.3% 84d | Missed |
DROP2022-09-12$94.18 RISE2022-09-27$79.64 PEAK2022-12-08$122.67 87d | -15.4% 15d | Missed | Missed | — | — | +54.0% 72d | Missed |
DROP2022-04-01$132.89 RISE2022-06-16$67.99 PEAK2022-09-12$94.18 164d | -48.8% 76d | Missed | Missed | — | — | +38.5% 88d | Missed |
DROP2021-11-17$162.82 RISE2022-02-23$94.08 PEAK2022-04-01$132.89 135d | -42.2% 98d | Missed | Missed | — | — | +41.3% 37d | Missed |
DROP2021-04-28$106.44 RISE2021-05-13$80.99 PEAK2021-08-05$130.98 99d | -23.9% 15d | Missed | Missed | — | — | +61.7% 84d | Missed |
DROP2021-02-19$104.74 RISE2021-03-18$84.79 PEAK2021-04-28$106.44 68d | -19.0% 27d | Missed | Missed | — | — | +25.5% 41d | Missed |
DROP2020-10-26$104.50 RISE2021-01-27$87.41 PEAK2021-02-19$104.74 116d | -16.4% 93d | Missed | Missed | — | — | +19.8% 23d | Missed |
DROP2020-08-05$112.95 RISE2020-11-02$78.00 PEAK2021-01-08$97.02 156d | -30.9% 89d | Missed | Missed | — | — | +24.4% 67d | Missed |
DROP2020-05-11$105.34 RISE2020-06-04$86.21 PEAK2020-08-05$112.95 86d | -18.2% 24d | Missed | Missed | — | — | +31.0% 62d | Missed |
1–15 / 16 1 / 2 | |||||||
DexCom’s latest valuation work now centers on a fair value anchor of US$81.64, slightly below the prior US$83.54 level and closer to the current range of Street targets. Many firms have trimmed price targets after recent Analyst/Investor Day updates, reflecting a balance between confidence in execution and a more cautious stance on longer term growth and valuation assumptions. As you read on, you will see how these shifting targets, together with fresh guidance and product news, shape the...
Google Ventures, Dexcom, and Blue Cross Blue Shield of Alabama backed the round as demand for weight loss tools grows
SAN DIEGO, May 26, 2026--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties.
The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.
The Standard & Poor's 500 index rose 0.9% this week, its eighth consecutive week of gains, amid upbe
The Standard & Poor's 500 index rose 0.9% this week, its eighth consecutive week of gains, amid upbe
Toronto, Ontario--(Newsfile Corp. - May 22, 2026) - QuantumCore Ltd. (CSE: QNCR) (FSE: K1Y) ("QuantumCore" or the "Company") is pleased to announce that David Marantz has been appointed to the Company's board of directors (the "Appointment"). David Marantz is a technology and healthcare executive with over 15 years of experience scaling high-growth companies, raising capital, and leading strategic transformations across healthcare, benefits, and SaaS. Mr. Marantz currently serves as the chief...
DexCom (NasdaqGS:DXCM) has launched Dexcom Flex, a new continuous glucose monitoring system for Type 2 diabetes patients who are not on intensive insulin therapy. The product is initially rolling out in Germany, expanding access to CGM technology for a broader group of patients. Dexcom Flex targets a segment of the Type 2 population that has historically had limited exposure to CGM devices. DexCom is best known for its CGM systems used by people with diabetes to track glucose levels in real...
DexCom (NasdaqGS:DXCM) has launched Dexcom Flex, a new continuous glucose monitoring system for Type 2 diabetes patients who are not on intensive insulin therapy. The product is initially rolling out in Germany, expanding access to CGM technology for a broader group of patients. Dexcom Flex targets a segment of the Type 2 population that has historically had limited exposure to CGM devices. DexCom is best known for its CGM systems used by people with diabetes to track glucose levels in real...
The Oura Ring creator’s plans to go public follow a $900m fundraise in October 2025 that put the company at an $11bn valuation.
The Oura Ring creator’s plans to go public follow a $900m fundraise in October 2025 that put the company at an $11bn valuation.
Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund lost 7.14% in the quarter, tied to a 6.75% fall in March due to the War in Iran. This compares to the S&P 500’s -4.33% return for […]
Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund lost 7.14% in the quarter, tied to a 6.75% fall in March due to the War in Iran. This compares to the S&P 500’s -4.33% return for […]
DexCom's improved fundamentals and a 15% lower stock price present a more attractive entry. Learn why DXCM stock is a Buy.
Oura Inc., which was valued at about $11 billion as of October, makes rings that track metrics such as heart rate and skin temperature, and are intended to help improve sleep and reduce stress.
The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.
DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the prior day’s 96% “Sell” rating and 100% “Sell” last week. A positive trend on that indicator. DXCM is...
DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the prior day’s 96% “Sell” rating and 100% “Sell” last week. A positive trend on that indicator. DXCM is...
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| DXCM | +20.20% | -0.05% | +11.10% | -14.06% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +17.23% | +5.66% | +14.55% | -26.74% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 17.93M | $1.13B | 0.04% | Trimmed-0.9% | 2026-03-31 |
| Wellington | fundamental | 9.33M | $585.69M | 0.11% | Added+203.4% | 2026-03-31 |
| FidelityFMR | fundamental | 1.67M | $105.07M | 0.01% | Added+28.8% | 2026-03-31 |
| RenTech | quant | 1.58M | $99.41M | 0.16% | Added+9.6% | 2026-03-31 |
| TwoSigma | quant | 1.11M | $70.02M | 0.06% | Added+3.0% | 2026-03-31 |
| Citadel | multi-strat | 257.3K | $16.16M | 0.02% | Trimmed-78.9% | 2026-03-31 |
| Bridgewater | macro | 139.7K | $8.77M | 0.04% | Trimmed-6.4% | 2026-03-31 |
| DEShaw | quant | 27.7K | $1.74M | 0.00% | Trimmed-99.3% | 2026-03-31 |
| TRowePrice | fundamental | 1.45M | $90.78K | 0.01% | Trimmed-1.6% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-27 | Coleman Jon | EVP, Chief Commercial Officer | F Tax withholding | 7,362 | $71.90 | −$529.3K |
| 2026-05-27 | Stern Sadie | EVP Chief People & Culture Off | F Tax withholding | 1,451 | $71.90 | −$104.3K |
| 2026-05-27 | Sylvain Jereme M | EVP, Chief Financal Officer | F Tax withholding | 1,451 | $71.90 | −$104.3K |
| 2026-05-27 | Brown Michael Jon | EVP Chief Legal Compliance Off | F Tax withholding | 1,451 | $71.90 | −$104.3K |
| 2026-05-27 | Leach Jacob Steven | President, CEO, and Director | F Tax withholding | 1,451 | $71.90 | −$104.3K |
| 2026-05-26 | SAYER KEVIN R | Executive Chair | S Open-market sale | 26,759 | $72.00 | −$1.93M |
| 2026-05-19 | Brown Michael Jon | EVP, Chief Legal Officer | S Open-market sale | 1,700 | $59.91 | −$101.8K |
| 2026-05-14 | Heller Bridgette P | Director | S Open-market sale | 1,012 | $60.01 | −$60.7K |
| 2026-04-16 | Brown Michael Jon | EVP, Chief Legal Officer | S Open-market sale | 1,700 | $63.04 | −$107.2K |
| 2026-03-18 | Brown Michael Jon | EVP, Chief Legal Officer | S Open-market sale | 1,700 | $64.85 | −$110.2K |
| 2026-03-10 | Coleman Jon | EVP, Chief Commercial Officer | A Grant / award | 43,897 | — | +$0 |
| 2026-03-10 | Leach Jacob Steven | President, CEO, and Director | F Tax withholding | 19,757 | $68.10 | −$1.35M |
| 2026-03-10 | Leach Jacob Steven | President, CEO, and Director | A Grant / award | 104,516 | — | +$0 |
| 2026-03-10 | Stern Sadie | EVP, Chief HR Officer | F Tax withholding | 17,199 | $68.10 | −$1.17M |
| 2026-03-10 | Stern Sadie | EVP, Chief HR Officer | A Grant / award | 39,019 | — | +$0 |
| 2026-03-10 | Brown Michael Jon | EVP, Chief Legal Officer | F Tax withholding | 23,325 | $68.10 | −$1.59M |
| 2026-03-10 | Brown Michael Jon | EVP, Chief Legal Officer | A Grant / award | 39,019 | — | +$0 |
| 2026-03-10 | Sylvain Jereme M | EVP, Chief Financal Officer | F Tax withholding | 18,950 | $68.10 | −$1.29M |
| 2026-03-10 | Sylvain Jereme M | EVP, Chief Financal Officer | A Grant / award | 48,774 | — | +$0 |
| 2026-03-10 | SAYER KEVIN R | Executive Chair | F Tax withholding | 32,498 | $68.10 | −$2.21M |
| 2026-03-10 | SAYER KEVIN R | Executive Chair | A Grant / award | 32,749 | — | +$0 |
| 2026-02-26 | Osterloh Albert Frederick IV | Director | A Grant / award | 7,061 | — | +$0 |
| 2026-02-17 | Heller Bridgette P | Director | S Open-market sale | 1,012 | $68.01 | −$68.8K |
| 2026-02-02 | SAYER KEVIN R | Executive Chair | F Tax withholding | 34,257 | $73.36 | −$2.51M |
| 2026-02-02 | SAYER KEVIN R | Executive Chair | A Grant / award | 71,218 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-29upcoming | 0.61 | — | — |
| 2026-04-30 | 0.45 | 0.51 | +12.62% |
| 2026-02-12 | 0.65 | 0.68 | +4.50% |
| 2025-10-30 | 0.57 | 0.61 | +7.51% |
| 2025-07-30 | 0.44 | 0.48 | +8.25% |
| 2025-05-01 | 0.33 | 0.32 | -2.56% |
| 2025-02-13 | 0.48 | 0.38 | -21.15% |
| 2024-10-24 | 0.43 | 0.45 | +3.53% |
| 2024-07-25 | 0.39 | 0.43 | +11.36% |
| 2024-04-25 | 0.27 | 0.32 | +18.61% |
| 2024-02-08 | 0.43 | 0.50 | +16.01% |
| 2023-10-26 | 0.33 | 0.50 | +50.03% |
| 2023-07-27 | 0.23 | 0.34 | +50.64% |
| 2023-04-27 | 0.15 | 0.17 | +17.05% |
| 2023-02-09 | 0.28 | 0.34 | +23.06% |
| 2022-10-27 | 0.24 | 0.28 | +15.85% |